Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, a self-developed biological product aimed at treating atopic dermatitis [1] Group 1: Product Development - SHR-1894 injection is expected to protect the skin barrier and suppress inflammation during the treatment of atopic dermatitis [1] - Currently, there are no similar drugs approved for market use domestically or internationally [1] - The total research and development investment for the SHR-1894 injection project has reached approximately 40.1 million yuan (unaudited) [1]

Core Viewpoint - The announcement indicates that the subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. of Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of SHR-1894 injection, which is expected to play a role in treating atopic dermatitis by protecting the skin barrier and inhibiting inflammation [1] Group 1: Product Development - SHR-1894 injection is a self-developed therapeutic biological product by the company [1] - The clinical trial for SHR-1894 injection will commence shortly following the approval [1] - The total research and development investment for the SHR-1894 injection project has reached approximately 40.1 million yuan [1] Group 2: Market Context - Currently, there are no similar drugs approved for market release domestically or internationally [1]

Core Viewpoint - The approval of clinical trial for DR10624 injection by NMPA marks a significant advancement in the drug development process for Zhejiang Daor Bio, enhancing the company's competitiveness in the endocrine treatment field [1][4]. Drug Information - Drug Name: DR10624 injection - IND Acceptance Number: CXSL2501013 - Indication: Hypertriglyceridemia (HTG) - Applicant: Zhejiang Daor Bio - Conclusion: The clinical trial application for DR10624 injection has been approved to conduct trials for HTG [1][2]. R&D and Registration Status - DR10624 is a first-in-class long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, developed independently by Daor Bio [2]. - The drug has successfully completed Phase II clinical studies for severe hypertriglyceridemia (sHTG) with positive topline results, showing a maximum liver fat reduction of 89% and over 70% relative reduction in triglycerides [3]. - The drug's Phase II clinical study results for sHTG were presented at AHA Scientific Sessions 2025, demonstrating significant reductions in triglyceride levels and liver fat content compared to placebo [3]. - DR10624 has also received approval for clinical trials in China for indications related to type 2 diabetes and weight management [3]. Impact on the Company - The approval of the clinical trial for DR10624 injection is a crucial step in the product's development, which is expected to enhance the company's core competitiveness in the endocrine treatment sector [4].

Financial Data and Key Metrics Changes - AbbVie reported full-year adjusted earnings per share of $10, exceeding initial guidance by $0.54, and total net revenues of $61.2 billion, surpassing guidance by over $2 billion [4][5] - Sales growth of 8.6% led to record net sales, exceeding previous peak revenue by more than $3 billion despite nearly $16 billion erosion from U.S. Humira [5][6] - Adjusted earnings per share for Q4 were $2.71, $0.08 above guidance midpoint, with total net revenues of $16.6 billion reflecting robust growth of 10% [33][34] Business Line Data and Key Metrics Changes - Immunology revenues reached approximately $8.6 billion in Q4, with Skyrizi sales of $5 billion (31.9% operational growth) and Rinvoq sales of nearly $2.4 billion (28.6% operational growth) [10][11] - Neuroscience full-year revenues exceeded $10.7 billion, with Q4 revenues of over $2.9 billion (17.3% operational growth), driven by Vraylar and Botox Therapeutic [17][18] - Oncology revenues were nearly $1.7 billion in Q4, down 2.5% operationally, with Venclexta sales of $710 million (6.4% operational growth) [19][20] Market Data and Key Metrics Changes - Global sales for Skyrizi in IBD reached approximately $6.4 billion in 2025, more than double the prior year's performance [13] - Humira delivered global sales of over $1.2 billion, down 26.1% operationally due to biosimilar competition [17] - The aesthetics segment saw global sales of nearly $1.3 billion in Q4, down 1.2% operationally, with Botox Cosmetic revenues of $717 million (3.8% operational growth) [20][21] Company Strategy and Development Direction - AbbVie plans to deliver total sales growth of 9.5% in 2026, driven by Skyrizi and Rinvoq, with combined sales expected to exceed $31 billion [6][7] - The company is focused on advancing its pipeline with significant investments in R&D, including over $5 billion in new business development [5][6] - A voluntary agreement with the U.S. government aims to enhance patient access and affordability while committing $100 billion in U.S. R&D and capital investments over the next decade [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in AbbVie's strong position to deliver high single-digit revenue growth through 2029, despite headwinds from Humira erosion and Imbruvica pricing [6][9] - The company anticipates key catalysts in R&D across immunology, neuroscience, and oncology over the next 24 months [8][9] - Management highlighted the potential for sustained long-term growth driven by innovative therapies and strategic acquisitions [9][10] Other Important Information - AbbVie increased adjusted R&D expense by nearly $1 billion in 2025, fully funding 90 clinical programs currently in development [5][6] - The company expects to generate free cash flow of approximately $18.5 billion in 2026, supporting a strong and growing quarterly dividend [39][40] Q&A Session Summary Question: Details on the psychedelic therapy in development - Management highlighted the potential of the psychedelic therapy to provide immediate efficacy with a short-acting profile, aiming for a breakthrough in treatment [41][42] Question: Insights on Skyrizi in IBD and market expectations - Management confirmed stable new patient starts for Skyrizi in both Crohn's and UC, with high capture rates despite competition [44][46] - They expressed confidence in the long-term growth potential for Skyrizi and Rinvoq, indicating that current market models may not fully reflect this upside [48][49] Question: Update on external innovation and business development - AbbVie has invested over $8 billion in external innovation, focusing on early-stage opportunities to drive growth in immunology, neuroscience, and oncology [52][54] Question: Expectations for Rinvoq and Lutikizumab phase 3 data - Management emphasized the importance of upcoming studies for Rinvoq and Lutikizumab, particularly in treatment failure populations, and expressed optimism based on previous performance [55][56]

Financial Data and Key Metrics Changes - Novartis achieved 8% sales growth and 14% core operating income growth for the full year 2025, with a core margin of 40.1%, reached two years ahead of plan [5][34][36] - For Q4, sales declined by 1%, while core operating income increased by 1%, with underlying growth of 3% when excluding one-time adjustments [6][38] - Core EPS rose 17% to $8.98, and free cash flow reached an all-time high of CHF 17.6 billion, growing 8% [34][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% to CHF 4.8 billion for the year, with Q4 growth at 44% [7][8] - Kesimpta grew 36% to $4.4 billion, with a 27% growth in Q4 [10][11] - Pluvicto reached $2 billion in sales, showing 42% constant currency growth [12] - Leqvio achieved blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Novartis reported strong growth in key markets, with Kisqali leading in early breast cancer settings in Germany with over 80% NBRX share [8] - Kesimpta is leading in 9 out of 10 major markets outside the U.S. [11] - Pluvicto has secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement power [7] - The company is committed to maintaining a strong pipeline with seven pivotal readouts expected in 2026 [31][49] - Novartis plans to continue investing in R&D, with over $10 billion allocated in 2025 [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 5%-6% sales CAGR from 2025 to 2030, despite anticipated generic impacts [42][48] - The company expects to return to a core margin of over 40% by 2029 [43] - Management highlighted the importance of pipeline assets in driving future growth [49] Other Important Information - The company completed a CHF 15 billion share buyback program and proposed a dividend increase of 6% [40][27] - The transition of CFO from Harry Kirsch to Mukul Mehta was noted, with Kirsch acknowledging the company's transformation during his tenure [41] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management confirmed that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [54][56] Question: Commercial opportunities for remibrutinib in MS - Management indicated that while B-cell monoclonal antibodies will remain dominant, there is a significant market for oral options, especially for patients preferring non-injectable therapies [61] Question: Risks associated with Pelacarsen's event-based study - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [63]

Core Viewpoint - The company is advancing its TSLP monoclonal antibody for the treatment of moderate to severe COPD, with significant progress in clinical trials, positioning it as a leader in the domestic market for similar projects [1] Clinical Development - The Phase II clinical trials are progressing smoothly, and the Phase III clinical trial has completed CDE filing, with preparations underway [1] - The product targets the upstream TSLP pathway to block airway inflammation at its source, showing potential to reduce acute exacerbation rates in patients [1] Competitive Landscape - Currently, only AstraZeneca/Amgen's Tezepelumab has been commercialized, approved solely for asthma, while COPD indications are still in Phase III trials globally [1] - Other domestic companies are exploring similar indications, but the company's focus on COPD and its leading development progress provide a significant competitive edge [1] Market Strategy - The company has a well-established academic promotion system and commercialization channels in the respiratory field, enabling rapid market integration upon product launch [1] - Future plans include accelerating clinical progress, seizing research and registration opportunities, and exploring additional indications to maximize market potential [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for its innovative drug BEBT-701, which targets both AGT and PCSK9 for the treatment of mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [1] Group 1 - The drug BEBT-701 is a globally first-of-its-kind small interfering RNA (siRNA) medication [1] - The approval allows the company to initiate Phase I-II clinical trials for BEBT-701 [1] - The development of the drug involves a lengthy research cycle, multiple approval stages, and significant investment, leading to various uncertainties [1]

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of the drug Fluorobiphenyl Patch [1] - The product is designed with a controlled-release membrane, featuring a large drug load, low irritation, and reduced risk of skin allergies, making it suitable for chronic pain conditions [2] - The original research product has not yet been launched in the domestic market and is classified as a Class 3 chemical drug [1] Group 2 - The approval of this clinical trial is expected to enhance the company's product portfolio in the musculoskeletal field, complementing its core products and improving its "internal + external" orthopedic solutions [3] - The market for similar products, such as Fluorobiphenyl Gel Patch, is significant, with sales reaching 2.839 billion yuan in 2024 and 2.350 billion yuan in the first three quarters of 2025 [2]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $772 million, resulting in 4% organic growth, with a full year revenue of $2.86 billion, reflecting 3% organic growth [22][24] - Adjusted EPS for the fourth quarter was $1.70, exceeding the high end of expectations, while the full year adjusted EPS was $5.06, representing 3% growth year-over-year [10][24] - Adjusted operating margins for the fourth quarter were 29.7%, down 60 basis points year-over-year, while full year adjusted operating margins were 27.1%, down 120 basis points year-over-year [23][24] Business Line Data and Key Metrics Changes - The diagnostics segment generated $390 million in revenue for the fourth quarter, up 10% on a reported basis and 7% on an organic basis, with full year organic growth of 4% [28] - The life sciences segment reported revenue of $382 million in the fourth quarter, flat on an organic basis, with full year organic growth also at 2% [26][27] - The immunodiagnostics business grew in the high single digits organically in the fourth quarter, while the reproductive health business grew mid-single digits [28][30] Market Data and Key Metrics Changes - Geographically, the company experienced flat performance in both the Americas and APAC, while Europe saw double-digit growth [26] - For the full year, the Americas grew low single digits, Europe grew high single digits, and APAC declined in the low single digits [26] Company Strategy and Development Direction - The company plans to continue its focus on capital deployment, including share repurchases and potential acquisitions, while maintaining a disciplined approach [11][20] - The introduction of the AI models-as-a-service platform, Signals Synthetica, is expected to enhance the company's position in the market [15][16] - The company anticipates organic growth of 2%-3% for 2026, with potential upside if market conditions improve [12][31] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets, particularly in pharma and biotech, while acknowledging ongoing uncertainties [11][12] - The company noted improvements in customer sentiment and funding in the biotech sector, contributing to a more favorable outlook [52] - Management emphasized the importance of maintaining a prudent approach in light of recent market trends and uncertainties [12][31] Other Important Information - The company repurchased over $800 million worth of shares in 2025, reducing the share count by 8.5 million shares [10][11] - The acquisition of ACD/Labs is expected to contribute over $20 million in revenue for the year, adding approximately 75 basis points to overall revenue growth [13][31] Q&A Session Summary Question: Can you provide more color on the 2%-3% organic growth guidance? - Management acknowledged positive signs in end markets since September but maintained the conservative guidance to allow for potential upside as the year unfolds [39][40] Question: What is driving the strength in instruments and reagents within life sciences? - Management indicated that continued momentum in the end market and share gains in the preclinical market are contributing factors [45] Question: Can you elaborate on the timing and trajectory of new software products? - Management highlighted that the Signals business is in a significant new product introduction phase, with expectations for growth to accelerate in the coming years [48][49] Question: How is the company approaching M&A opportunities? - Management stated that any potential M&A must provide a strong strategic addition and meet financial return criteria [56] Question: What are the expectations for the diagnostics business going into 2026? - Management expressed a more prudent assumption for newborn screening and immunodiagnostics in China, while still anticipating potential upside [64][70]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $772 million, resulting in 4% organic growth, with a full year revenue of $2.86 billion, reflecting 3% organic growth [20][21] - Adjusted EPS for the fourth quarter was $1.70, exceeding guidance, while full year adjusted EPS was $5.06, representing a 3% year-over-year growth [9][23] - Adjusted operating margins for the fourth quarter were 29.7%, down 60 basis points year-over-year, while full year adjusted operating margins were 27.1%, down 120 basis points year-over-year [21][24] Business Line Data and Key Metrics Changes - The diagnostics segment achieved 7% organic growth in the fourth quarter, with full year organic growth of 4%, driven by strong performance in immunodiagnostics and reproductive health [6][27] - The life sciences segment remained flat year-over-year in organic growth for the fourth quarter, with full year organic growth also at 2%, impacted by low single-digit declines in academic and government sales [6][26] - Signals software business grew in the high teens organically for the full year, with a nearly 40% ARR growth compared to last year [26] Market Data and Key Metrics Changes - Geographically, the company experienced flat performance in both the Americas and APAC, while Europe saw double-digit growth [25] - For the full year, the Americas grew low single digits, Europe grew high single digits, and APAC declined in the low single digits [25] Company Strategy and Development Direction - The company plans to reinvest a portion of operational upside back into the business, focusing on employee support and capital deployment opportunities [10][19] - The acquisition of ACD/Labs is expected to contribute over $20 million in total revenue, adding approximately 75 basis points to overall revenue growth [12][30] - The introduction of the AI models-as-a-service platform, Signals Synthetica, is aimed at enhancing drug development processes [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets, reiterating a 2%-3% organic growth outlook for 2026 [11][29] - The company acknowledged recent positive trends in pharma and biotech funding, but remains prudent in its initial outlook due to ongoing market uncertainties [10][20] - Management highlighted the importance of maintaining a disciplined approach to capital deployment while navigating a fluid end market and policy environment [10][19] Other Important Information - The company repurchased over $800 million worth of shares in 2025, reducing the share count by 8.5 million shares [9][10] - Free cash flow for the fourth quarter was $162 million, resulting in 84% conversion of adjusted net income, with full year free cash flow at $515 million [24] Q&A Session Summary Question: Insights on the 2%-3% organic growth guidance - Management acknowledged positive signs in end markets since September but maintained the conservative guidance to allow for potential upside as the year unfolds [39][40] Question: Factors driving strength in life sciences instruments and reagents - Management indicated that improvements in preclinical spending and ongoing demand development are key drivers, with a focus on maintaining market share [45][46] Question: Timing and trajectory of new software product launches - Management confirmed that the Signals business is in a significant new product introduction phase, with expectations for growth rates to accelerate over the coming years [49][50] Question: Performance within pharma biotech and order trends - Management noted cautious optimism in order trends, with improvements attributed to greater clarity in the policy and regulatory environment [61][62] Question: Outlook for diagnostics business and potential upside - Management highlighted strong performance in newborn screening and immunodiagnostics, suggesting potential for upside in diagnostics for 2026 [65][66]